Đang chuẩn bị liên kết để tải về tài liệu:
Jonsson et al. Journal of Translational Medicine 2011, 9:114

Jonsson et al. Journal of Translational Medicine 2011, 9:114 http://www.translational-medicine.com/content/9/1/114 RESEARCH Open Access Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study Liv Jonsson1†, Julia Bergman1†, Björn Nodin1, Jonas Manjer2,3, Fredrik Pontén4, Mathias Uhlén5,6 and Karin Jirström1* Abstract Background: We have previously reported that expression of the RNA- and DNA-binding protein RBM3 is associated with a good prognosis in breast cancer and ovarian cancer. In this study, the prognostic value of immunohistochemical RBM3 expression was assessed in incident cases of malignant melanoma from a prospective population-based cohort study. Methods:. | Jonsson et al. Journal of Translational Medicine 2011 9 114 http www.translational-medicine.eom content 9 1 114 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma An analysis of 215 cases from the Malmo Diet and Cancer Study 1 f 1 f 1 2.3 4 56 1 Liv Jonsson T Julia Bergman T Bjorn Nodin Jonas Manjer Fredrik Pontén Mathias Uhlén and Karin Jirstrom Abstract Background We have previously reported that expression of the RNA- and DNA-binding protein RBM3 is associated with a good prognosis in breast cancer and ovarian cancer. In this study the prognostic value of immunohistochemical RBM3 expression was assessed in incident cases of malignant melanoma from a prospective population-based cohort study. Methods Until Dec 31st 2008 264 incident cases of primary invasive melanoma had been registered in the Malmo Diet and Cancer Study. Histopathological and clinical information was obtained for available cases and tissue microarrays TMAs constructed from 226 85.6 suitable paraffin-embedded tumours and 31 metastases. RBM3 expression was analysed by immunohistochemistry on the TMAs and a subset of full-face sections. Chi-square and Mann-Whitney U tests were used for comparison of RBM3 expression and relevant clinicopathological characteristics. Kaplan Meier analysis and Cox proportional hazards modelling were used to assess the relationship between RBM3 and recurrence free survival RFS and overall survival OS . Results RBM3 could be assessed in 215 226 95.1 of primary tumours and all metastases. Longitudinal analysis revealed that 16 31 51.6 of metastases lacked RBM3 expression in contrast to the primary tumours in which RBM3 was absent in 3 215 1.4 cases and strongly expressed in 120 215 55.8 cases. Strong nuclear RBM3 expression in the primary tumour was significantly associated with favourable clinicopathological parameters i.e. non-ulcerated tumours lower depth of .